Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Accumulated Depreciation (2017 - 2025)

Protagonist Therapeutics' Accumulated Depreciation history spans 8 years, with the latest figure at $7.9 million for Q3 2025.

  • For Q3 2025, Accumulated Depreciation changed N/A year-over-year to $7.9 million; the TTM value through Sep 2025 reached $7.9 million, changed N/A, while the annual FY2024 figure was $7.0 million, 12.85% up from the prior year.
  • Accumulated Depreciation for Q3 2025 was $7.9 million at Protagonist Therapeutics, up from $7.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $7.9 million in Q3 2025 and bottomed at $4.3 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation is $6.1 million (2023), against an average of $6.0 million.
  • The largest annual shift saw Accumulated Depreciation grew 23.39% in 2022 before it increased 12.85% in 2024.
  • A 5-year view of Accumulated Depreciation shows it stood at $4.3 million in 2021, then rose by 23.39% to $5.3 million in 2022, then rose by 18.65% to $6.2 million in 2023, then grew by 12.85% to $7.0 million in 2024, then grew by 12.85% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Accumulated Depreciation are $7.9 million (Q3 2025), $7.0 million (Q4 2024), and $6.7 million (Q2 2024).